Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • emc易倍官网入口Media Resources
    • Media Contacts
    • emc易倍官网入口Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • emc易倍官网入口Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • emc易倍官网入口Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • emc易倍官网入口Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • emc易倍官网入口Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • Brazil
    • Canada
    • United States
    • Mexico
    • Australia
    • China
    • emc易倍官网入口 Singapore
    • South Korea
    • emc易倍官网入口 Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • emc易倍官网入口 Nordics
    • Greece
    • Italy
    • emc易倍官网入口 Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Romania
    • Hungary
    • Slovakia
    • emc易倍官网入口 Switzerland
    • emc易倍官网入口 Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • emc易倍官网入口Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • emc易倍官网入口Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • emc易倍官网入口Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • emc易倍官网入口Collaborate with us
  • Stories
  1. Home
  2. emc易倍官网入口Newsroom – Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€157.50

 €-3.10 (-1.93%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • emc易倍官网入口Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?







2026-07-16 23:44:24